Tosoh Bioscience expands the renowned TSKgel SW series of aqueous size exclusion HPLC columns by three new UHPLC columns, tailored to different aspects of antibody analysis.
Tosoh Bioscience expands the renowned TSKgel SW series of aqueous size exclusion HPLC columns by three new UHPLC columns, tailored to different aspects of antibody analysis.
SEC on silica based stationary phases is state of the art for aggregation analysis. TSKgel G3000SWXL is regarded as the gold standard of antibody SEC columns. In an ongoing approach to adopt stationary phases to the user’s needs, the proven surface chemistry of the TSKgel SW series was used to developed new UHPLC columns.
TSKgel SuperSW mAb HTP – ‘HTP’ for high throughput – was developed to enable easy transfer of HPLC methods based on TSKgel SWXL to fast UHPLC analysis. Small particle size silica beads featuring the same pore size and coating as G3000SWXL are packed in UHPLC column hardware with 4.6 mm inner diameter. This allows for doubling the throughput without compromising resolution between monomer and dimer. Another approach was used in the development of TSKgel SuperSW mAb HR – ‘HR’ indicating high resolution. The SuperSW stationary phase was packed in columns featuring the traditional dimensions for HPLC gel filtration columns of 7.8 mm ID and 30 cm length. This results in superior resolution between fragments, monomers, and aggregates. TSKgel UltraSW Aggregate covers the range of higher molecular weights and provides very good separation of antibody dimers and higher aggregates. It is based on even smaller silica beads with slightly larger pore size.
The new columns are ideally used in UHPLC instruments, even though the columns will not create back pressures exceeding the pressure limits of standard HPLC systems.
Tosoh Bioscience
Zettachring 6, 70567 Stuttgart, Germany
[email protected]
www.tosohbioscience.de
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.